These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16490801)

  • 1. So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics.
    Williams JA; Johnson K; Paulauskis J; Cook J
    J Clin Pharmacol; 2006 Mar; 46(3):258-64. PubMed ID: 16490801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.
    Fanta S; Niemi M; Jönsson S; Karlsson MO; Holmberg C; Neuvonen PJ; Hoppu K; Backman JT
    Pharmacogenet Genomics; 2008 Feb; 18(2):77-90. PubMed ID: 18192894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
    Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
    Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics in breast cancer therapy.
    Tan SH; Lee SC; Goh BC; Wong J
    Clin Cancer Res; 2008 Dec; 14(24):8027-41. PubMed ID: 19088019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
    Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
    Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
    Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
    Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.
    Kim KA; Park PW; Lee OJ; Choi SH; Min BH; Shin KH; Chun BG; Shin JG; Park JY
    Clin Pharmacol Ther; 2006 Dec; 80(6):646-56. PubMed ID: 17178265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M; Petrovic N
    Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
    Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
    Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
    Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of pharmacogenomics.
    Somogy A
    Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects.
    Kim KA; Park PW; Park JY
    Chirality; 2009 May; 21(5):485-91. PubMed ID: 18752284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
    Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
    Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
    Lai Y; Varma M; Feng B; Stephens JC; Kimoto E; El-Kattan A; Ichikawa K; Kikkawa H; Ono C; Suzuki A; Suzuki M; Yamamoto Y; Tremaine L
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):723-43. PubMed ID: 22509796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
    Wang J
    Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic factors in drug metabolism.
    Belle DJ; Singh H
    Am Fam Physician; 2008 Jun; 77(11):1553-60. PubMed ID: 18581835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms.
    Schaefer M; Roots I; Gerloff T
    Pharmacogenet Genomics; 2006 Dec; 16(12):855-61. PubMed ID: 17108809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
    Petain A; Kattygnarath D; Azard J; Chatelut E; Delbaldo C; Geoerger B; Barrois M; Séronie-Vivien S; LeCesne A; Vassal G;
    Clin Cancer Res; 2008 Nov; 14(21):7102-9. PubMed ID: 18981009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.